Question · asked by 1 review
Interferon-alpha 1000 IU lozenges (topical) vs Interferon-alpha 2000 IU lozenges (topical): Total ulcer burden
- Population
- People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
- Intervention
- Interferon-alpha 1000 IU lozenges (topical)
- Comparison
- Interferon-alpha 2000 IU lozenges (topical)
- Outcome
- Total ulcer burden
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Interferon-alpha 1000 IU lozenges (topical) vs Interferon-alpha 2000 IU lozenges (topical) Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · Interferon-alpha dose comparison Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane All outcomes | Kilic 2009 (interferon-alpha 1000 IU vs 2000 IU lozenges, 84 patients): the data presented did not allow analysis; authors reported no statistically significant difference in total ulcer burden between the two doses. | 1 study · 84 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes | 2013-10 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.